UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) | Delaware | 01-0382980 | | --- | --- | | (State of incorporation) | (I.R.S. Employer | | | Identification No.) | | 56 Evergreen Drive, Portland, Maine | 04103 | | (Address of principal exec ...

ImmuCell Corp (NASDAQ:ICCC) Q4 2021 Earnings Conference Call February 23, 2022 9:00 AM ET Company Participants Michael Brigham – President, Chief Executive Officer Joe Diaz – Lytham Partner Betsy Williams – Vice President of Manufacturing Operations Bobbi Jo Brockmann – Vice President of Sales & Marketing Conference Call Participants George Melas – MKH Managements Tom Fox – Private Investor Operator Good morning and welcome to ImmuCell Corporation's fourth quarter fiscal year 2021 financial results. My name ...

ImmuCell Corp (NASDAQ:ICCC) Q3 2021 Earnings Conference Call November 16, 2021 9:00 AM ET Company Participants Joe Diaz - Lytham Partner Michael Brigham - President, CEO, Principal Financial Officer, Treasurer, Secretary & Director Conference Call Participants Scott Billeadeau - Walrus Partners Operator Good morning. This is Betsy from Chorus Call. I will be assisting with your conference call this morning. To get things started, let me ask Joe Diaz to open up the call. Joe Diaz Thank you, Betsy. Good morni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) | Delaware | 01-0382980 | | --- | --- | | (State of Incorporation) | (I.R.S. Employer | | | Identification No.) | | 56 Evergreen Drive, Portland, ME | 04103 | | (Address of princi ...

ImmuCell Corporation (NASDAQ:ICCC) Q2 2021 Earnings Conference Call August 13, 2021 9:00 AM ET Company Participants Joe Diaz - Managing Partner at Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants Sam Rebotsky - SER Asset Management Operator Good day, and welcome to the ImmuCell Corporation reports Second Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, t ...

| --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------| | | | | | | ImmuCell Corporation Investor Presentation August 2021 | | | | | | | | | Forward-Looking Statements Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) | Delaware | 01-0382980 | | --- | --- | | (State of Incorporation) | (I.R.S. Employer | | | Identification No.) | | 56 Evergreen Drive, Portland, ME | 04103 | | (Address of principal e ...

Company Overview and Strategic Focus - ImmuCell aims to capitalize on the growth of First Defense® product line and revolutionize subclinical mastitis treatment with Re-Tain™[5] - The company focuses on delivering Immediate Immunity™ to newborn calves, improving herd productivity without unnecessary dam vaccine injections[5] - ImmuCell is addressing the $2 billion annual economic harm caused by mastitis infections without traditional antibiotics, using Re-Tain™[5] Product Lines and Market Opportunities - First Defense® targets the U S market with approximately $23 4 million in annual sales for calf-level scours prevention products[12] - The company estimates the U S market for dam-level vaccine products to prevent scours is almost 2X the calf-level product sales[13] - Re-Tain™ targets the mastitis market, estimated to cause approximately $2 billion in economic loss to the dairy industry each year[14, 25] Financial Performance and Capital Expenditures - As of March 31, 2021, ImmuCell had $6 8 million in cash and cash equivalents and $9 7 million in net working capital[42] - The company completed an investment of approximately $3 5 million to increase First Defense® production capacity from approximately $16 5 million to approximately $23 million[13, 23] - ImmuCell is constructing a $21 million pharmaceutical production facility for Re-Tain™[14, 24] Sales Growth and Market Share - Total product sales have grown with a 13% CAGR from 2011-2020, reaching $15 3 million in 2020[35] - The company's calf-level U S market share has increased from 34% in 2017 to 41% in 2020[19]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) | Delaware | 01-0382980 | | --- | --- | | (State of Incorporation) | (I.R.S. Employer | | | Identification No.) | | 56 Evergreen Drive, Portland, ME | 04103 | | (Address of principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.10 per share (Title of class) Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑ Indicate by check mark if the Registrant is not requi ...